# Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer

> **NCT01314027** · PHASE3 · TERMINATED · sponsor: **University of Zurich** · enrollment: 38 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin
- **DRUG:** adjuvant chemotherapy with gemcitabine

## Key facts

- **NCT ID:** NCT01314027
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2018-12
- **Final completion:** 2019-05
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** low recruitment
- **Last updated:** 2019-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314027, "Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01314027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*